Moderna Stock Plunges Despite ‘Vaccine Day’ Touting 31 New Shots And $21 Billion In Sales—Here’s Why
- Saturday, March 26, 2022, 7:23
- Market
- Add a comment
One analyst blasted Moderna’s flu vaccine results as a “nonstarter” clinically, while others said investors are still too focused on Covid.
About the Author
admin123 has written 23412 stories on this site.
